Effect of Intravitreal Bevacizumab on Early Post-Vitrectomy Hemorrhage in Diabetic Patients

Sponsor
Shahid Beheshti University of Medical Sciences
Study ID
NCT00524875
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    One dose of bevacizumab (1.25 mg/0.05 cc) one to two weeks before pars plana vitrectomy for diabetic retinopathy

Study Details

The purpose of this study is to determine whether bevacizumab 1-2 weeks before vitrectomy is effective in lowering the rate of early post-vitrectomy vitreous hemorrhage in diabetic patients.

Key Dates

First listed
Sep 5, 2007
Start date
Jan 31, 2007
Status verified
Aug 2007
Completion
Sep 30, 2007

Study Design

Enrollment
80 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Experimental: 1
    Intravitreal bevacizumab injection 1-2 weeks before surgery
  • Sham Comparator: 2
    Sham injection (needleless syringe pressed against conjunctiva)

Primary Outcome Measure

early post-vitrectomy vitreous hemorrhage

Central Contacts

Related Studies